Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial ( STOP‐OB )-Reference-Cited by-同舟云学术

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial ( STOP‐OB )

Published:2020-05-07 Issue:9 Volume:22 Page:1659-1663
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kitazawa Toru¹,Seino Hiroaki²,Ohashi Hiroshi³,Inazawa Takeshi⁴,Inoue Masahiro⁵,Ai Masumi⁶⁷,Fujishiro Midori⁸⁹,Kuroda Hisamoto¹⁰,Yamada Masayo¹¹,Anai Motonobu¹²¹³,Ishihara Hisamitsu⁸⁹^ORCID

Affiliation:

1. Division of Diabetes, Endocrinology and Metabolism, Department of MedicineTokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

2. Seino Internal Medicine Clinic Koriyama Japan

3. Internal MedicineOyama East Clinic Oyama Japan

4. Department of Endocrinology and MetabolismKashiwa City Hospital Kashiwa Japan

5. Sasazuka Inoue Clinic Tokyo Japan

6. Tanaka Clinic Wako Japan

7. Department of Insured Medical Care Management, Graduate School of Medical and Dental SciencesTokyo Medical and Dental University Tokyo Japan

8. Division of Diabetes and Metabolism, Department of Internal MedicineNihon University School of Medicine Tokyo Japan

9. Department of Internal MedicineNihon University Hospital Tokyo Japan

10. Green Clinic Mibu Japan

11. Division of Metabolism and Endocrinology, Department of Internal MedicineYokohama Sakae Kyosai Hospital Yokohama Japan

12. Research Center for Advanced Science and TechnologyThe University of Tokyo Tokyo Japan

13. Division of Diabetes and MetabolismThe Institute for Adult Diseases, Asahi Life Foundation Tokyo Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14059

Reference20 articles.

1. Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database

2. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

3. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

4. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

5. Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review;Pharmaceuticals;2024-04-29

2. Effect of baseline urinary glucose levels on the relationship between sodium-glucose cotransporter 2 inhibitors and serum uric acid in Japanese patients with type 2 diabetes mellitus;PHARMAZIE;2023

3. The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review;Diabetes Therapy;2023-10-14

4. Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;Frontiers in Endocrinology;2023-09-15

5. Impact of tofogliflozin on hepatic outcomes: a systematic review;European Journal of Clinical Pharmacology;2023-07-18